Cambrex Reports Third Quarter 20...(--------- --------- Adjusted EBITD...),Health

Date:11/3/2009

--------- --------- Adjusted EBITDA $37,725 $37,266 ========= ========= * During 2008, the Company incurred expenses related to restructuring activities and strategic alternative expenses pursuant to the sale of its Bioproducts and Biopharma businesses in February 2007 and for the consolidation of the New Jersey R&D facility. These costs are identified within the 2008 income statement and have been excluded from the calculation of certain profit measurements, including Adjusted EBITDA for 2008. ** During 2008, the Company incurred expenses related to the acceleration of equity awards to its former CEO. These costs are included within Selling, General and Administrative Expenses and have been excluded from the calculation of certain profit measurements, including Adjusted EBITDA for 2008. CAMBREX CORPORATION Consolidated Balance Sheet As of September 30, 2009 and December 31, 2008 (in thousands) September 30, December 31, Assets 2009 2008 --------- --------- Cash and Cash Equivalents $45,345 $32,540 Trade Receivables, net 37,466 36,685 Inventories, net 61,341 61,133 Prepaid Expenses and Other Current Assets 9,193 8,798 --------- --------- Total Current Assets 153,345 139,156 Property, Plant and Equipment, net 166,303 161,500 Goodwill
'/>"/>

SOURCE Cambrex Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
2. Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA